89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, Pegozafermin, is being developed for the treatment of MASH and for the treatment of SHTG. Pegozafermin is a specifically engineered glycoPEGylated analog of FGF21. 89bio is headquartered in San Francisco with operations in Herzliya, Israel.